Duopharma secures higher cumulative profit

PETALING JAYA: Duopharma Biotech Bhd is positive about the prospects of the pharmaceutical sector on the back of a positive growth momentum in Malaysia’s economy following the reopening of international borders and continuous emphasis by the government on the healthcare sector.

Managing director Leonard Ariff Abdul Shatar is optimistic the company would be able to deliver a satisfactory performance for 2022, in light of the strong demand from the private ethical market and public health sector, and despite manufacturing margin pressure from a strong US dollar.